INOVIQ Limited (ASX:IIQ) is an Australian biotechnology company developing diagnostic and therapeutic applications based on its proprietary exosome technology platform. The company's pipeline includes the EXO-OC ovarian cancer diagnostic, the SubB2M family of cancer diagnostic tests and preclinical therapeutic programs targeting solid tumours. INOVIQ also has a commercial research-tools Business based on its EXO-NET pan-exosome isolation technology. As of 12 August 2026, the company was trading at A$0.19, after touching an intraday high of A$0.20, with the stock unchanged on the day.

What is INOVIQ focused on?

INOVIQ is focused on developing technologies that use exosomes and other extracellular vesicles for cancer diagnosis, research and potential therapeutic applications.

Exosomes are small biological structures released by cells that carry molecular information. Researchers are investigating their potential use as biomarkers because they can contain proteins, nucleic acids and other biological material associated with the cells from which they originate.

INOVIQ's technology platform is designed to isolate and analyse exosomes and apply that capability to diagnostic and research applications.

What is the EXO-OC diagnostic?

EXO-OC is INOVIQ's ovarian cancer diagnostic program. The test is being developed to identify biomarkers associated with ovarian cancer and potentially support earlier detection.

Ovarian cancer can be difficult to identify at an early stage because its symptoms can be non-specific and may overlap with other conditions. A diagnostic technology capable of identifying disease earlier could therefore have significant clinical relevance.

INOVIQ has been undertaking clinical development work on EXO-OC, including expanded studies and algorithm development. Further clinical evidence will be important in determining the diagnostic performance and potential applications of the test.

US commercialisation strategy

INOVIQ has outlined an initial US launch strategy for its ovarian cancer test focused on high-risk women through a laboratory-developed test pathway.

A laboratory-developed test can provide a route for certain diagnostic tests to reach the market through laboratory-based services, subject to applicable regulatory and compliance requirements. INOVIQ's proposed approach is therefore an important part of its commercialisation strategy.

The company will need to progress the relevant technical, clinical, laboratory and regulatory requirements before the commercial potential of the US strategy can be fully established.

EXO-NET research tools

Beyond its diagnostic pipeline, INOVIQ has developed EXO-NET, a research tool designed for pan-exosome isolation.

The technology is intended to support researchers working with extracellular vesicles and exosome-related applications. INOVIQ has established commercial relationships around its research tools, including a Partnership with US life-sciences company Promega.

This commercial activity provides the company with a source of Revenue while its diagnostic and therapeutic programs continue through development.

Broader development pipeline

INOVIQ's technology platform extends beyond EXO-OC. The company is also developing the SubB2M family of cancer diagnostic tests and maintaining a preclinical therapeutics program targeting solid tumours.

The SubB2M technology is based on the identification of cancer-associated molecules and is being investigated for applications in cancer diagnostics.

The therapeutic program represents an earlier-stage component of the pipeline and remains subject to further laboratory and preclinical development.

Recent company developments

INOVIQ has continued to advance its diagnostic programs through clinical and technical work during 2026. Updates have included algorithm development for EXO-OC, clinical study activities and communication of study findings.

The company also held its Life Science Investor Day in February 2026, outlining its technology platform, development pipeline and broader strategy across diagnostics and therapeutics.

INOVIQ completed a Capital raising during 2026 and continues to operate as a development-stage biotechnology company. Its financial resources are therefore directed toward advancing its technology platform, clinical programs, regulatory activities and commercial operations.

Commercial development opportunities

The combination of diagnostic development and research-tool revenue gives INOVIQ exposure to multiple areas of the life-sciences market.

A successful EXO-OC program could potentially create a diagnostic product addressing ovarian cancer detection, while the EXO-NET business provides applications for researchers working with extracellular vesicles.

The longer-term potential of the platform will depend on the ability to demonstrate reproducible diagnostic performance, satisfy regulatory requirements, develop commercial partnerships and achieve adoption within relevant healthcare and research markets.

Key challenges

INOVIQ operates in a highly competitive biotechnology and diagnostics environment. Diagnostic development requires robust clinical evidence demonstrating performance across appropriate patient populations.

Regulatory requirements are another important consideration. The proposed US laboratory-developed test pathway involves compliance obligations, and the regulatory environment for laboratory-developed tests continues to evolve.

The company also remains in a development phase, with expenditure required for clinical programs, regulatory activities, technology development and commercialisation. Continued access to sufficient funding will therefore be important as programs progress.

Commercial adoption represents another challenge. Even when a diagnostic demonstrates strong technical performance, achieving widespread use can require clinical acceptance, laboratory integration, reimbursement support and partnerships.

What to watch next

Future EXO-OC clinical and technical updates will be important in assessing the development of INOVIQ's ovarian cancer diagnostic.

Progress with the company's US laboratory-developed test strategy will also be significant, particularly as it moves from development toward potential commercialisation.

Additional research-tool partnerships, licensing arrangements and commercial developments around EXO-NET could provide further information about the company's ability to generate revenue from its technology platform.

Updates concerning the SubB2M diagnostic programs and preclinical therapeutic research will also provide insight into the breadth and progression of the company's pipeline.

Current share performance

As of 12 August 2026, INOVIQ was trading at A$0.19, with the stock unchanged on the day. The shares touched an intraday high of A$0.20 during the session.

Conclusion

INOVIQ (ASX:IIQ) is developing an exosome-based technology platform spanning cancer diagnostics, research tools and potential therapeutics. Its EXO-OC ovarian cancer diagnostic is a key development program, while EXO-NET provides a commercial research application for the company's underlying technology.

The proposed US laboratory-developed test pathway represents an important component of the company's commercialisation strategy. At the same time, clinical validation, regulatory requirements, funding needs and commercial adoption remain central factors in the development of the business.

The progress of EXO-OC, expansion of EXO-NET commercial activity and advancement of the broader diagnostic and therapeutic pipeline will be important areas of focus as INOVIQ continues developing its platform.